Compare efficacy and safety data for new and emerging treatments for second-line extensive-stage-SCLC (ES-SCLC), as well as for immunotherapies approved in subsequent lines
|
|
|
|
|
|
Identify strategies for best supportive care to enhance quality of life in patients with relapsed or refractory ES-SCLC
|
|
|
|
|
|